ITT AND SPERM

Testosterone threshold required for spermatogenesis

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Deslyn Cognome: Brown Email: send email Telefono: +44 20 8383 8339 Fax: +44 20 8383 2208
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	178˙307 €
EC contributo	178˙307 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-2-1-IEF
Funding Scheme	MC-IEF
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-07-15   -   2008-10-14

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Deslyn Cognome: Brown Email: send email Telefono: +44 20 8383 8339 Fax: +44 20 8383 2208	UK (LONDON)	coordinator	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Follicle-stimulating hormone and high intratesticular (IT) testosterone (T) level are required for qualitatively normal spermatogenesis. Treatment with T has been successfully tested in male contraception, because it can abolish gonadotrophin secretion through enhanced negative feedback action and arrest spermatogenesis. However, none of the T treatment regimens tested have resulted in complete azoospermia in all men, for reasons not yet understood. After complete T induced suppression of gonadotrophins, the residual ITT levels are 2% of normal, yet similar to those in peripheral circulation. The residual constitutively produced ITT could be the reason for the suboptimal contraceptive efficacy. The purpose of this study is to address in details the dependence of spermatogenesis and its suppression during contraceptive treatments on ITT level. The particular aim of this proposal will be to demonstrate in experimental conditions (mice) that the necessary peripheral androgen actions and spermatogenic arrest can be achieved simultaneously, which is fundamental for the functionality of an androgen based male hormonal contraceptive. The project will be articulated on three major objectives: (i) to determine the threshold of T replacement dose that maintains peripheral androgen actions without stimulating spermatogenesis; (ii) to design a way to suppress ITT production below the level achieved by gonadotrophin blockage, and (iii) to design a way to increase the efficacy and safety margin of T replacement dose by blockage of the constitutive T production. We expect that these experimental studies will show that it is important to eliminate the gonadotrophin independent component of ITT to maximise the efficacy of male hormonal contraception. In addition, this project permits the researcher to undertake the research with a view to completing and diversifying her expertise in molecular biology and endocrinology and pursue her career in academic research.'